Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Community Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Complement Ther Clin Pract. 2021 Aug;44:101443. doi: 10.1016/j.ctcp.2021.101443. Epub 2021 Jul 13.
Kefir is a fermented beverage obtained as a result of lactic-alcoholic fermentation of milk by using kefir grains or a starter culture. Kefir beverage has numerous health benefits owing to its antimicrobial, anti-inflammatory and anti-diabetic properties, while it could also regulate the gut microbiota. This beverage is recommended as a nutritional approach to glycemic control. This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of kefir beverage on the glycemic control. For this purpose, a literature search was conducted via databases such as PubMed, Scopus, ISI Web of Science, and Google Scholar for the articles published until July 2020 with no limitation. The indicators of glycemic control were fasting blood sugar (FBS), hemoglobin A1c (HbA1c), and insulin. In total, six RCTs on a total sample size of 323 subjects were selected for the meta-analysis. Inverse-variance weighted mean difference (WMD) with a 95% confidence interval (CI) was calculated for the mean changes in HbA1c, FBG and insulin compared to baseline. Considering the clinical heterogeneity caused by the varied duration and dosage of kefir beverage treatment, a random effects model was used to estimate the pooled WMD. Findings indicated a more significant reduction in the FBS (WMD = -10.28; 95% CI: -16.53-4.02; P = 0.001) and insulin (WMD = -2.87; 95% CI: -3.96-1.78; P < 0.00001) in the kefir treatment group. Furthermore, kefir consumption could reduce HbA1c (HbA1c = -0.64 -1.36, 0.08), while this effect was not considered significant (-0.64; 95% CI: -1.36-0.08; P = 0.08). The results of our meta-analysis indicated that kefir beverage could reduce the FBS and insulin levels without a significant effect on HbA1c. In general, our findings showed that kefir beverages may have beneficial effects on glycemic control. However, more clinical data and research into the mechanism of probiotics are required to clarify the beneficial effects of probiotics on glycemic markers.
克菲尔是一种发酵饮料,通过使用克菲尔粒或起始培养物使牛奶进行乳酸-酒精发酵而获得。由于其具有抗菌、抗炎和抗糖尿病的特性,克菲尔饮料对健康有诸多益处,同时还可以调节肠道微生物群。该饮料被推荐作为控制血糖的营养方法。本系统评价和随机对照试验(RCT)的荟萃分析旨在评估克菲尔饮料对血糖控制的影响。为此,通过 PubMed、Scopus、ISI Web of Science 和 Google Scholar 等数据库对截至 2020 年 7 月发表的文章进行了无限制的文献检索。血糖控制的指标是空腹血糖(FBS)、糖化血红蛋白(HbA1c)和胰岛素。共有 6 项针对 323 名受试者的 RCT 被纳入荟萃分析。采用逆方差加权均数差值(WMD)和 95%置信区间(CI)比较治疗前后 HbA1c、FBG 和胰岛素的平均变化。考虑到克菲尔饮料治疗的持续时间和剂量不同引起的临床异质性,采用随机效应模型估计汇总 WMD。结果表明,FBS(WMD=-10.28;95%CI:-16.53-4.02;P=0.001)和胰岛素(WMD=-2.87;95%CI:-3.96-1.78;P<0.00001)的降低更为显著在克菲尔治疗组中。此外,克菲尔的摄入可以降低 HbA1c(HbA1c=-0.64-1.36,0.08),但这种效果并不显著(HbA1c=-0.64;95%CI:-1.36-0.08;P=0.08)。荟萃分析的结果表明,克菲尔饮料可以降低 FBS 和胰岛素水平,而对 HbA1c 没有显著影响。总的来说,我们的研究结果表明,克菲尔饮料可能对血糖控制有有益的影响。然而,需要更多的临床数据和对益生菌机制的研究来阐明益生菌对血糖标志物的有益作用。